Violehealth is preparing to open its first investigator-initiated grant cycle. Funding will prioritize functional characterization of loss-of-function KCNQ2 variants at the PIP2-binding site — including Violetta’s R325M variant — and early gene-supplementation models.
Researchers interested in applying can register their interest now; full application guidelines will follow ahead of the opening date.